Immunome, Inc. (IMNM)
- Previous Close
15.50 - Open
15.60 - Bid 15.59 x 400
- Ask 15.67 x 400
- Day's Range
15.55 - 16.79 - 52 Week Range
4.50 - 30.96 - Volume
827,485 - Avg. Volume
741,780 - Market Cap (intraday)
935.716M - Beta (5Y Monthly) 1.88
- PE Ratio (TTM)
-- - EPS (TTM)
-5.38 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.33
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
immunome.comRecent News: IMNM
Performance Overview: IMNM
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMNM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMNM
Valuation Measures
Market Cap
935.72M
Enterprise Value
795.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.10
Price/Book (mrq)
7.81
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.81%
Return on Equity (ttm)
-156.45%
Revenue (ttm)
14.02M
Net Income Avi to Common (ttm)
-106.81M
Diluted EPS (ttm)
-5.38
Balance Sheet and Cash Flow
Total Cash (mrq)
142.15M
Total Debt/Equity (mrq)
1.38%
Levered Free Cash Flow (ttm)
2.36M
Research Analysis: IMNM
Company Insights: IMNM
IMNM does not have Company Insights